Advertisement

Journal of Fetal Medicine

, Volume 5, Issue 4, pp 233–236 | Cite as

A Case of Coumarin Embryopathy After in Utero Exposure to Acenocoumarol

  • Ankur Singh
  • Astha Panghal
  • Rajniti Prasad
  • Om Prakash Mishra
Brief Communication
  • 6 Downloads

Abstract

Coumarins (warfarin, acenocoumarol, phenprocuomon) are well known agents that are prescribed for prevention of thromboembolic episodes in pregnant women who are on mechanical heart valves prosthesis. It acts as double edge sword as fetus is unnecessarily exposed to teratogenic effect of drug. Warfarin is well studied drug in terms of its tetratogenic dose, period of exposure, fetopathic effects. Acenocoumarol is well known teratogen but its effect and lethal dose on fetus is less reported. We report a neonate who was exposed to acenocoumarol throughout intra uterine life. Neonate showed all features of coumarin embryopathy (flat facial profile, depressed nasal bridge, short columella, skeletal stippling, short distal phalanges in hand) and cephalhaematoma in addition. We also summarised the clinical findings of all the cases reported so far of acenocoumarol embryopathy. Acenocoumarol has same teratogenic potential as of warfarin. Doses causing embryopathy remained unexplored field. Clinicians need to document properly so that scientific data can be generated as ethical issues arises in head to head trial of these drugs.

Keywords

Acenocoumarol Embryopathy Chondrodysplasia Calcification Mid face hypoplasia 

Notes

Authors’ Contribution

AS and AP collected the data and AS conceptualized the idea and wrote the manuscript and is first author. RP helped in case management and manuscript writing. OPM critically analysed the manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declared that they have no conflict of interest.

References

  1. 1.
    Ban A. Long-term treatment with coumarin preparations in advanced age. Z Gesamte Inn Med. 1984;39:617–20.Google Scholar
  2. 2.
    Vigue B. Bench-to-bedside review: optimising emergency reversal of vitamin K antagonists in severe hemorrhage—from theory to practice. Crit Care. 2009;13:209.CrossRefGoogle Scholar
  3. 3.
    Van Driel D, Wesseling J, Sauer PJ, et al. Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis. Teratology. 2002;66:127–40.CrossRefGoogle Scholar
  4. 4.
    McLintock C. Anticoagulant therapy in pregnant women with mechanical prosthetic heart valves: no easy option. Thromb Res. 2011;127:S56–60.CrossRefGoogle Scholar
  5. 5.
    Panduranga P, El-Deeb M, Jha C. Mechanical prosthetic valves and pregnancy: a therapeutic dilemma of anticoagulation. Sultan Qaboos Univ Med J. 2014;14:e448–54.Google Scholar
  6. 6.
    Suri V, Keepanasseril A, Aggarwal N, et al. Mechanical valve prosthesis and anticoagulation regimens in pregnancy: a tertiary centre experience. Eur J Obstet Gynecol Reprod Biol. 2011;159:320–3.CrossRefGoogle Scholar
  7. 7.
    Prieto AL, Weber JL, Tracy S, et al. Gas6, a ligand for the receptor protein-tyrosine kinase Tyro-3, is widely expressed in the central nervous system. Brain Res. 1999;816:646–61.CrossRefGoogle Scholar
  8. 8.
    Hou JW. Fetal warfarin syndrome. Chang Gung Med J. 2004;27:691–5.Google Scholar
  9. 9.
    Becker MH, Genieser NB, Finegold M, et al. Chondrodysplasia Punctata. Is maternal warfarin therapy a factor? Am J Dis Child. 1975;129:356–9.CrossRefGoogle Scholar
  10. 10.
    Howe AM, Webster WS. Vitamin K: its essential role in craniofacial development. A review of the literature regarding vitamin K and craniofacial development. Aust Dent J. 1994;39:88–92.CrossRefGoogle Scholar
  11. 11.
    Vanlaeys R, Deroubaix P, Deroubaix G, et al. Les antivitamines K sont-elles te´ratoge`nes? Nouv Press Med. 1977;6:756.Google Scholar
  12. 12.
    Weenink GH, van Dijk-Wierda CA, Meyboom RH, et al. Teratogenic effect of coumarin derivatives. Ned Tijdschr Geneeskd. 1981;125:702–6.Google Scholar
  13. 13.
    Lapiedra OJ, Bernal JM, Ninot S, et al. Open heart surgery for thrombosis of a prosthetic mitral valve during pregnancy. Fetal hydrocephalus. J Cardiovasc Surg (Torino). 1986;27:217–20.Google Scholar
  14. 14.
    De Vries TW, Van der Veer E, Heymans HSA. Warfarin embryopathy: patient, possibility, pathogenesis and prognosis. Br J Obstet Gynaecol. 1993;100:869–71.CrossRefGoogle Scholar
  15. 15.
    Van Driel D, Wesseling J, De Vries TW, et al. Coumarin embryopathy: follow-up of two cases. Eur J Pediatr. 2002;161:231–2.CrossRefGoogle Scholar
  16. 16.
    Bony C, Zyka F, Tiran-Rajaofera I, et al. Warfarin fetopathy. Arch Pediatr. 2002;9:705–8.CrossRefGoogle Scholar
  17. 17.
    Robinow M, Johnson GF. Dermatoglyphics in distal phalangeal hypoplasia. Am J Dis Child. 1972;124:860–3.Google Scholar
  18. 18.
    Hassouna A, Allam H. Limited dose warfarin throughout pregnancy in patients with mechanical heart valve prosthesis: a meta-analysis. Interact CardioVasc Thorac Surg. 2014;18:797–806.CrossRefGoogle Scholar
  19. 19.
    Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68:122–40.CrossRefGoogle Scholar

Copyright information

© Society of Fetal Medicine 2018

Authors and Affiliations

  • Ankur Singh
    • 1
  • Astha Panghal
    • 1
  • Rajniti Prasad
    • 1
  • Om Prakash Mishra
    • 1
  1. 1.Genetic Clinic, Department of Paediatrics, Institute Of Medical SciencesBanaras Hindu UniversityVaranasiIndia

Personalised recommendations